Cas9 Stable Cell Line - MCF 10A

The MCF 10A-Cas9 stable cell line is the preferred model for studying human breast biology. It is established by integrating the Cas9 nuclease into the human MCF 10A cell line. MCF 10A is a non-tumorigenic, adherent epithelial cell line derived from patients with benign fibrocystic breast disease. A key characteristic of MCF 10A cells is their ability to represent “normal” breast epithelium, as they lack common oncogenic mutations and require specific growth factors for proliferation. Constitutive expression of Cas9 in this cell line provides an efficient and reproducible platform for CRISPR-mediated gene editing, ensuring consistent editing capabilities across all cells. This stable system enables precise gene manipulation on near-normal human cell models, providing a foundation for studying the initial steps of breast cancer development and the maintenance of breast tissue structure.

The primary applications of the MCF 10A-Cas9 stable cell line are studying the development and progression of breast cancer and screening for factors driving malignant transformation. Researchers use this cell line for CRISPR screening to identify genes involved in epithelial-mesenchymal transition (EMT), cell polarity regulation, and growth factor-independent mechanisms. The MCF 10A-Cas9 cell line is particularly well-suited for constructing homologous clones to study how specific gene mutations (such as BRCA1/2 or PIK3CA mutations) alter the behavior of “normal” breast cells. Furthermore, it serves as a reliable platform for studying breast development and assessing the toxicity of environmental factors and drugs to breast tissue. Its well-defined non-transformation state and stable Cas9 expression make it an indispensable resource for understanding the transformation of human breast tissue from a healthy to a malignant state.